Initially, we administered CRC-EVs (including CT26-EVs and MC38-EVs) via intraperitoneal injection to ascertain whether they could prompt activation of the macrophage αvβ3-STAT3 signaling pathway in vivo. This evidence concerns the gene DDX53 and colorectal carcinoma.